BEATRICE Study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche
ClinicalTrials.gov Identifier:
NCT00528567
First received: September 11, 2007
Last updated: September 17, 2013
Last verified: September 2013
  Purpose

This 2 arm open-label study is evaluating the efficacy and safety of the addition of Avastin (bevacizumab) to standard adjuvant therapy in patients with triple negative breast cancer. Patients were randomized to receive either standard chemotherapy (anthracycline +/- taxane or taxane only), or standard chemotherapy given concurrently with 1 year of Avastin (5mg/kg/week dosing equivalent i.v.). The anticipated time on study treatment was 3-12 months, and the target sample size was 500+ individuals.


Condition Intervention Phase
Breast Cancer
Drug: bevacizumab [Avastin]
Drug: Standard adjuvant chemotherapy
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open Label 2-arm Study to Evaluate the Impact of Adjuvant Bevacizumab on Invasive Disease Free Survival in Triple Negative Breast Cancer

Resource links provided by NLM:


Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Time to Invasive Disease-free Survival (IDFS) Event [ Time Frame: Event driven (until data cutoff: 29 February 2012 up to 49 months) ] [ Designated as safety issue: No ]
    IDFS, was a composite endpoint defined as the time from randomization until the date of the first occurrence of one of the following events: Ipsilateral invasive breast cancer recurrence (same breast); Ipsilateral (same side of body) local regional invasive breast cancer recurrence (axilla, regional lymph nodes, chest wall, and/or skin); Distant recurrence (evidence of breast cancer in any anatomic site);Death attributable to any cause; Contralateral (opposite side of the body) invasive breast cancer or Second primary non-breast invasive cancer.

  • Percentage of Participants With Invasive Disease-free Survival (IDFS) Events [ Time Frame: Event driven (until data cutoff: 29 February 2012 up to 49 months) ] [ Designated as safety issue: No ]
    IDFS, was a composite endpoint defined as the time from randomization until the date of the first occurrence of one of the following events: Ipsilateral invasive breast cancer recurrence (same breast); Ipsilateral (same side of body) local regional invasive breast cancer recurrence (axilla, regional lymph nodes, chest wall, and/or skin); Distant recurrence (evidence of breast cancer in any anatomic site);Death attributable to any cause; Contralateral (opposite side of the body) invasive breast cancer or Second primary non-breast invasive cancer. The percentage of participants with and without IDFS Events by the time of the data cutoff is presented.

  • Time to Invasive Disease-free Survival (IDFS) Event Excluding Second Primary Non-Breast Invasive Cancer [ Time Frame: Event driven (until data cutoff: 29 February 2012: up to 49 months) ] [ Designated as safety issue: No ]
    IDFS, was a composite endpoint defined as the time from randomization until the date of the first occurrence of one of the following events: Ipsilateral invasive breast cancer recurrence (same breast); Ipsilateral (same side of body) local regional invasive breast cancer recurrence (axilla, regional lymph nodes, chest wall, and/or skin); Distant recurrence (evidence of breast cancer in any anatomic site); Death attributable to any cause; Contralateral (opposite side of the body) invasive breast cancer.

  • Percentage of Participants With Invasive Disease-free Survival (IDFS) Events Excluding Second Primary Non-Breast Invasive Cancer [ Time Frame: Event driven (until data cutoff: 29 February 2012: up to 49 months) ] [ Designated as safety issue: No ]
    IDFS, was a composite endpoint defined as the time from randomization until the date of the first occurrence of one of the following events: Ipsilateral invasive breast cancer recurrence (same breast); Ipsilateral (same side of body) local regional invasive breast cancer recurrence (axilla, regional lymph nodes, chest wall, and/or skin); Distant recurrence (evidence of breast cancer in any anatomic site); Death attributable to any cause; Contralateral (opposite side of the body) invasive breast cancer. Percentage of participants with and without IDFS Events by the time of data cutoff is presented.


Secondary Outcome Measures:
  • Time to Overall Survival (OS) Event [ Time Frame: Event driven (until data cutoff: 29 February 2012 up to 49 months) ] [ Designated as safety issue: No ]
    OS was defined as the time from randomization to death attributable to any cause. Patients for whom no death is captured in the clinical database up to the clinical cut-off date are censored at the last time they were known to be alive.

  • Percentage of Participants With Overall Survival (OS) Events [ Time Frame: Event driven (until data cutoff: 29 February 2012 up to 49 months) ] [ Designated as safety issue: No ]
    OS was defined as the time from randomization to death attributable to any cause. Patients for whom no death is captured in the clinical database up to the clinical cut-off date are censored at the last time they were known to be alive. Percentage of participants with and without Overall Survival events by the time of data cutoff is presented.

  • Time to Breast Cancer-Free Interval (BCFI) Event [ Time Frame: Event driven (until data cutoff: 29 February 2012 up to 49 months) ] [ Designated as safety issue: No ]
    BCFI is defined as the time from randomization until the date of the first occurrence of one of the following events: Ipsilateral local/regional invasive breast cancer recurrence or distant breast cancer recurrence; Contralateral invasive breast cancer; Ipsilateral or contralateral Ductal carcinoma in situ or Death only from breast cancer cause.

  • Percentage of Participants With Breast Cancer-Free Interval (BCFI) Events [ Time Frame: Event driven (until data cutoff: 29 February 2012 up to 49 months) ] [ Designated as safety issue: No ]
    BCFI is defined as the time from randomization until the date of the first occurrence of one of the following events: Ipsilateral local/regional invasive breast cancer recurrence or distant breast cancer recurrence; Contralateral invasive breast cancer; Ipsilateral or contralateral DCIS or Death only from breast cancer cause. Percentage of participants with and without BCFI events by the time of the data cutoff is presented.

  • Time to Disease-Free Survival (DFS) Event [ Time Frame: Event driven (until data cutoff: 29 February 2012 up to 49 months) ] [ Designated as safety issue: No ]
    DFS is defined as the time from randomization until the date of the first occurrence of one of the following events: Ipsilateral invasive breast cancer recurrence (same breast); Ipsilateral (same side of body) local regional invasive breast cancer recurrence (axilla, regional lymph nodes, chest wall, and/or skin); Distant recurrence (evidence of breast cancer in any anatomic site); Death attributable to any cause; Contralateral (opposite side of the body) invasive breast cancer, Second primary non-breast invasive cancer or New diagnosis of an ipsilateral or contralateral Ductal carcinoma in situ (DCIS).

  • Percentage of Participants With Disease-Free Survival (DFS) Events [ Time Frame: Event driven (until data cutoff: 29 February 2012 up to 49 months) ] [ Designated as safety issue: No ]
    DFS is defined as the time from randomization until the date of the first occurrence of one of the following events: Ipsilateral invasive breast cancer recurrence (same breast); Ipsilateral (same side of body) local regional invasive breast cancer recurrence (axilla, regional lymph nodes, chest wall, and/or skin); Distant recurrence (evidence of breast cancer in any anatomic site); Death attributable to any cause; Contralateral (opposite side of the body) invasive breast cancer, Second primary non-breast invasive cancer or New diagnosis of an ipsilateral or contralateral Ductal carcinoma in situ (DCIS). Percentage of Participants with and without DFI Events by the time of the data cut-off is presented.

  • Time to Distant Disease-Free Survival (DDFS) Event [ Time Frame: Event driven (until data cutoff: 29 February 2012 up to 49 months) ] [ Designated as safety issue: No ]
    DDFS is defined as the time from randomization until the date of the first occurrence of one of the following events: Distant recurrence; Death attributable to any cause; Second primary non-breast invasive cancer (with the exception of non-melanoma Skin cancers).

  • Percentage of Participants With Distant Disease-Free Survival (DDFS) Events [ Time Frame: Event driven (until data cutoff: 29 February 2012 up to 49 months) ] [ Designated as safety issue: No ]
    DDFS is defined as the time from randomization until the date of the first occurrence of one of the following events: Distant recurrence; Death attributable to any cause; Second primary non-breast invasive cancer (with the exception of non-melanoma Skin cancers). Percentage of participants with and without DDFS Events by the time of the data cutoff is presented.

  • Number of Participants With Serious Adverse Events (SAEs), Adverse Events (AEs) and Deaths [ Time Frame: Up to 18 months for AEs and Up to 49 months for SAEs ] [ Designated as safety issue: No ]

    An adverse event was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study were reported as adverse events.

    A serious adverse event is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is Life-Threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.



Enrollment: 2591
Study Start Date: December 2007
Estimated Study Completion Date: January 2015
Primary Completion Date: February 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: bevacizumab and chemotherapy
bevacizumab 5 mg/kg/week intravenous every 2- 3 weeks based on body weight in combination with chemotherapy as prescribed (anthracycline containing without taxane every 3-4 weeks or anthracycline with taxane every 2-3 weeks or taxane containing without anthracycline every 3 weeks). Participants discontinued chemotherapy and were treated with bevacizumab only for total treatment with bevacizumab approximately 52 weeks or 18 3-week cycles. Participants then entered a follow-up period.
Drug: bevacizumab [Avastin]
5 mg/kg/week dosing equivalent intravenous (iv)
Drug: Standard adjuvant chemotherapy
As prescribed
Active Comparator: chemotherapy
Participants received chemotherapy as prescribed (anthracycline containing without taxane every 3-4 weeks or anthracycline with taxane every 2-3 weeks or taxane containing without anthracycline every 3 weeks). After completion of chemotherapy participants entered the follow-up period.
Drug: Standard adjuvant chemotherapy
As prescribed

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • adult patients, >=18 years of age;
  • operable primary invasive breast cancer;
  • completed definitive loco-regional surgery;
  • primary tumor centrally confirmed as triple negative.

Exclusion Criteria:

  • locally advanced breast cancers;
  • previous breast cancer history;
  • clinically significant cardiovascular disease.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00528567

  Hide Study Locations
Locations
United States, Alabama
Huntsville, Alabama, United States, 35805
Mobile, Alabama, United States, 36604
United States, Arkansas
Fayetteville, Arkansas, United States, 72703
United States, California
Bakersfield, California, United States, 93309
Fountain Valley, California, United States, 92708
Greenbrae, California, United States, 94904
Los Angeles, California, United States, 90057
Pleasant Hill, California, United States, 94523
United States, Connecticut
Fairfield, Connecticut, United States, 06824
Stamford, Connecticut, United States, 06902
United States, District of Columbia
Washington, District of Columbia, United States, 20010
United States, Florida
Gainesville, Florida, United States, 32605
Orlando, Florida, United States, 32806
Tamarac, Florida, United States, 33321
United States, Georgia
Atlanta, Georgia, United States, 30318
Augusta, Georgia, United States, 30901
Lawrenceville, Georgia, United States, 30046
United States, Illinois
Niles, Illinois, United States, 60714
United States, Iowa
Iowa City, Iowa, United States, 52242
Waterloo, Iowa, United States, 50702
United States, Maryland
Baltimore, Maryland, United States, 21237
Baltimore, Maryland, United States, 21215
Rockville, Maryland, United States, 20850-3348
United States, Michigan
Brownstown, Michigan, United States, 48183
Kalamazoo, Michigan, United States, 49007
Southfield, Michigan, United States, 48075-3707
United States, Missouri
Kansas City, Missouri, United States, 64111
St Louis, Missouri, United States, 63141
United States, New Jersey
Long Branch, New Jersey, United States, 07740
United States, New York
Bronx, New York, United States, 10469
United States, North Carolina
Hickory, North Carolina, United States, 28602
Winston-salem, North Carolina, United States, 27103
United States, Ohio
Cincinnati, Ohio, United States, 45242
Columbus, Ohio, United States, 43235
Middletown, Ohio, United States, 45042
United States, South Carolina
Columbia, South Carolina, United States, 29210
United States, Tennessee
Chattanooga, Tennessee, United States, 37404
Germantown, Tennessee, United States, 38138
Nashville, Tennessee, United States, 37203
United States, Texas
Austin, Texas, United States, 78759
Dallas, Texas, United States, 75234
United States, Vermont
Rutland, Vermont, United States, 05701
United States, Virginia
Abingdon, Virginia, United States, 24211
Richmond, Virginia, United States, 23230
Argentina
Buenos Aires, Argentina, C1405DCS
Rosario, Argentina, S2002KDS
Australia
Brisbane, Australia, 4104
Brisbane, Australia, 4006
Camperdown, Australia, 2050
East Bentleigh, Australia, VIC 3165
Fitzroy, Australia, 3065
Geelong, Australia, 3220
Heidelberg, Australia, 3084
Kurralta Park, Australia, 5035
Malvern, Australia, 3144
Nambour, Australia, 4560
Parkville, Australia, 3052
Perth, Australia, 6000
Perth, Australia, 6008
Port Macquarie, Australia, 2444
St. Leonards, Australia, 2065
Sydney, Australia, 2139
Sydney, Australia, 2065
Sydney, Australia, 2060
Sydney, Australia, 2031
Wahroonga, Australia, 2076
Waratah, Australia, 2298
Wodonga, Australia, 3690
Wollongong, Australia, 2500
Austria
Bludesch, Austria, 6712
Graz, Austria, 8036
Innsbruck, Austria, 6020
Krems, Austria, 4560
Leoben, Austria, 8700
Linz, Austria, 4020
Salzburg, Austria, 5020
Wels, Austria, 4600
Wien, Austria, 1090
Wien, Austria, 1130
Wiener Neustadt, Austria, 2700
Wolfsberg, Austria, 9400
Belgium
Baudour, Belgium, 7331
Bruxelles, Belgium, 1090
Hasselt, Belgium, 3500
Namur, Belgium, 5000
Sint-niklaas, Belgium, 9100
Tournai, Belgium, 7500
Wilrijk, Belgium, 2610
Bosnia and Herzegovina
Sarajevo, Bosnia and Herzegovina, 71000
Brazil
Goiania, Brazil, 74075-040
Ijui, Brazil, 98700-000
JAU, Brazil, 17210-120
Porto Alegre, Brazil, 90035-903
Porto Alegre, Brazil, 91350-200
Porto Alegre, Brazil, 90430-090
Rio de Janeiro, Brazil, 22260-020
Santo Andre, Brazil, 09060-870
Sao Paulo, Brazil, 05403
Sao Paulo, Brazil, 01209-010
Sao Paulo, Brazil, 1401000
Sao Paulo, Brazil, 01317-000
Sorocaba, Brazil, 18030-245
Canada, Alberta
Edmonton, Alberta, Canada, T6G 1Z2
Canada, British Columbia
Surrey, British Columbia, Canada, V3V 1Z2
Vancouver, British Columbia, Canada, V5Z 4E6
Canada, Manitoba
Winnipeg, Manitoba, Canada, R2H 2A6
Canada, New Brunswick
Moncton, New Brunswick, Canada, E1C 6Z8
Canada, Newfoundland and Labrador
St. John's, Newfoundland and Labrador, Canada, A1B 3V6
Canada, Nova Scotia
Halifax, Nova Scotia, Canada, B3H 2Y9
Canada, Ontario
Kingston, Ontario, Canada, K7L 5P9
Kitchener, Ontario, Canada, N2G 1G3
London, Ontario, Canada, N6A 4L6
Mississauga, Ontario, Canada, L5M 2N1
Oshawa, Ontario, Canada, L1G 2B9
Ottawa, Ontario, Canada, K1H 8L6
Sudbury, Ontario, Canada, P3E 5J1
Toronto, Ontario, Canada, M9N 1N8
Toronto, Ontario, Canada, M4N 3M5
Toronto, Ontario, Canada, M5G 2M9
Windsor, Ontario, Canada, N8W 2X3
Canada, Quebec
Greenfield Park, Quebec, Canada, J4V 2H1
Montreal, Quebec, Canada, H1T 2M4
Montreal, Quebec, Canada, H2W 1S6
Canada, Saskatchewan
Saskatoon, Saskatchewan, Canada, S7N 4H4
Canada
Quebec, Canada, G1S 4L8
China
Beijing, China, 100853
Beijing, China, 100071
Beijing, China, 100032
Beijing, China, 100021
Changchun, China, 130012
Chengdu, China, 610041
Fuzhou, China, 350025
Guangzhou, China, 510060
Hang Zhou, China, 310022
Shanghai, China, 200032
Suzhou, China, 215006
Tianjin, China, 300060
Wuhan, China, 430030
Zhejiang, China, 310003
Costa Rica
San Jose, Costa Rica, 10103
Czech Republic
Brno, Czech Republic, 656 53
Novy Jicin, Czech Republic, 741 01
Olomouc, Czech Republic, 775 20
Pardubice, Czech Republic, 532 03
Praha, Czech Republic, 150 06
Finland
Tampere, Finland, 33520
Turku, Finland, 20521
France
Angers, France, 49933
Bayonne, France, 64100
Besancon, France, 25030
Bobigny, France, 93009
Bordeaux, France, 33077
Brest, France, 29609
Clermont Ferrand, France, 63050
Colmar, France, 68024
Grenoble, France, 38100
La Chaussee St Victor, France, 41260
Le Mans, France, 72000
Lille, France, 59020
Lille, France, 59000
Limoges, France, 87039
Marseille, France, 13285
Montbeliard, France, 25209
Montpellier, France, 34298
Mougins, France, 6250
Nancy, France, 54100
Neuilly Sur Seine, France, 92200
Paris, France, 75231
Paris, France, 75908
Paris, France, 75010
Rouen, France, 76038
Saint-cloud, France, 92210
Senlis, France, 60309
Strasbourg, France, 67010
Toulon, France, 83056
Tours, France, 37044
Germany
Berlin, Germany, 10317
Berlin, Germany, 14195
Bielefeld, Germany, 33604
Bonn, Germany, 53111
Chemnitz, Germany, 09116
Coburg, Germany, 96450
Dortmund, Germany, 44137
Dresden, Germany, 01307
Düsseldorf, Germany, 40225
Frankfurt Am Main, Germany, 60389
Freiburg, Germany, 79106
Georgsmarienhütte, Germany, 49124
Greifswald, Germany, 17475
Hamburg, Germany, 20246
Hamburg, Germany, 20357
Heidelberg, Germany, 69115
Herne, Germany, 44625
Kassel, Germany, 34117
Kiel, Germany, 24105
Koeln, Germany, 50924
Krefeld, Germany, 47805
Leipzig, Germany, 04129
Lemgo, Germany, 32657
Lüneburg, Germany, 21339
Magdeburg, Germany, 39108
Marburg, Germany, 35043
München, Germany, 81925
Münster, Germany, 48149
Offenbach, Germany, 63069
Offenburg, Germany, 77654
Recklinghausen, Germany, 45657
Rosenheim, Germany, 83022
Stade, Germany, 21680
Trier, Germany, 54290
Tübingen, Germany, 72076
ULM, Germany, 89075
WEIßENFELS, Germany, 06667
Wiesbaden, Germany, 65199
Witten, Germany, 58452
Greece
Heraklion, Greece, 71110
Patras, Greece, 26500
Thessaloniki, Greece, 56429
Hong Kong
Hong Kong, Hong Kong
Hong Kong, Hong Kong, 852
Israel
Haifa, Israel, 31096
Jerusalem, Israel, 91120
Kfar Saba, Israel, 44281
Petach Tikva, Israel, 49100
Ramat-gan, Israel, 52621
Rehovot, Israel, 76100
Tel Aviv, Israel, 64239
Italy
Aviano, Italy, 33081
Bari, Italy, 70126
Bergamo, Italy, 24128
Brescia, Italy, 25123
Brindisi, Italy, 72100
Candiolo, Italy, 10060
Cattolica, Italy, 47841
Cesena, Italy, 47023
Fano, Italy, 61032
Genova, Italy, 16142
Lecce, Italy, 73100
Lido Di Camaiore, Italy, 55043
Livorno, Italy, 57100
Lugo, Italy
Mantova, Italy, 46100
Noale, Italy, 30033
Padova, Italy, 35128
Palermo, Italy, 90146
Parma, Italy, 43100
Pavia, Italy, 27100
Potenza, Italy, 85100
Ravenna, Italy, 48100
Rimini, Italy, 47037
Roma, Italy, 00158
Roma, Italy, 00161
Roma, Italy, 00144
Rozzano, Italy, 20089
San Giovanni Rotondo, Italy, 71013
Sassari, Italy, 07100
Taormina, Italy, 98039
Treviglio, Italy, 24047
Vecchiazzano, Italy, 47100
Japan
Aichi, Japan, 464-8681
Ehime, Japan, 791-0280
Fukuoka, Japan, 811-1395
Kyoto, Japan, 606-8507
Osaka, Japan, 540-0006
Saitama, Japan, 350-1298
Tokyo, Japan, 135-8550
Tokyo, Japan, 104-8560
Tokyo, Japan, 104-0045
Tokyo, Japan, 113-8677
Korea, Republic of
Kyunggi-do, Korea, Republic of, 411-769
Seoul, Korea, Republic of, 110-744
Seoul, Korea, Republic of, 138-736
Seoul, Korea, Republic of, 135-170
Seoul, Korea, Republic of, 137-702
Macedonia, The Former Yugoslav Republic of
Skopje, Macedonia, The Former Yugoslav Republic of, 1000
Malaysia
Kelantan, Malaysia
Penang, Malaysia, 11200
Petaling Jaya, Selangor, Malaysia, 46050
Selangor, Malaysia, 47500
Mexico
Leon, Mexico, 37000
Monterrey, Mexico, 64020
Netherlands
Delftzijl, Netherlands, 9934 JD
Den Helder, Netherlands, 1782GZ
Groningen, Netherlands, 9713 GZ
Tilburg, Netherlands, 5042 AD
New Zealand
Auckland, New Zealand
Wellington, New Zealand, 6002
Peru
Lima, Peru, 11
Philippines
Cebu, Philippines, 6000
Quezon City, Philippines, 1114
Poland
Elblag, Poland, 82-300
Lodz, Poland, 93-509
Lublin, Poland, 20-081
Lublin, Poland, 20-090
Poznan, Poland, 61-878
Warsaw, Poland, 61485
Warszawa, Poland, 02-781
Portugal
Coimbra, Portugal, 3000-075
Lisboa, Portugal, 1099-023
Lisboa, Portugal, 1649-035
Romania
Bucharest, Romania, 022328
Cluj Napoca, Romania, 400015
Russian Federation
Chelyabinsk, Russian Federation, 454 087
Ekaterinburg, Russian Federation, 620905
Ivanovo, Russian Federation, 153040
Kazan, Russian Federation, 420111
Kazan, Russian Federation, 420029
Moscow, Russian Federation, 121356
Moscow, Russian Federation, 117837
Moscow, Russian Federation, 115478
Obninsk, Russian Federation, 249036
Persochnysaint-petersburg, Russian Federation, 197758
Ryazan, Russian Federation, 390011
Samara, Russian Federation, 443066
St Petersburg, Russian Federation
UFA, Russian Federation, 450054
Serbia
Belgrade, Serbia, 11000
Sremska Kamenica, Serbia, 21204
Singapore
Singapore, Singapore, 169610
Singapore, Singapore, 119228
South Africa
Bloemfontein, South Africa, 9301
Durban, South Africa, 4001
Johannesburg, South Africa, 2196
Pietermaritzburg, South Africa, 3201
Pretoria, South Africa, 0181
Pretoria, South Africa, 0002
Spain
Barcelona, Spain, 08003
Barcelona, Spain, 08035
Burgos, Spain, 09005
Gijon, Spain, 33394
Girona, Spain, 17007
La Laguna, Spain, 38320
Madrid, Spain, 28033
Madrid, Spain, 28222
Madrid, Spain, 28046
Madrid, Spain, 28034
Madrid, Spain, 28041
Malaga, Spain, 29010
Mataro, Spain, 08304
Málaga, Spain, 29010
Navarra, Spain, 31008
Palma de Mallorca, Spain, 07014
Pontevedra, Spain, 36002
Terrassa, Spain, 08221
Valencia, Spain, 41014
Valencia, Spain, 46017
Zaragoza, Spain, 50009
Sweden
Eskilstuna, Sweden, 63188
Gaevle, Sweden, 80187
Lund, Sweden, 22185
Malmoe, Sweden, 20502
Umea, Sweden, 90185
Uppsala, Sweden, 751 85
Switzerland
Aarau, Switzerland, 5001
Basel, Switzerland, 4031
Bern, Switzerland, 3010
Chur, Switzerland, 7000
Thun, Switzerland, 3600
Winterthur, Switzerland, 8401
Zürich, Switzerland, 8008
Taiwan
Changhua, Taiwan, 500
Kaohsiung, Taiwan, 813
Kaohsiung, Taiwan, 807
Tainan, Taiwan, 704
Taipei, Taiwan, 112
Taipei, Taiwan, 114
Taipei, Taiwan, 100
Taoyuan, Taiwan, 333
Thailand
Bangkok, Thailand, 10400
Bangkok, Thailand, 10700
Chiang Mai, Thailand, 50200
Songkhla, Thailand, 90110
United Kingdom
Belfast, United Kingdom, BT9 7AB
Birmingham, United Kingdom, B15 2TT
Bournemouth, United Kingdom, BH7 7DW
Brighton, United Kingdom, BN2 5BE
Bristol, United Kingdom, BS2 8ED
Cambridge, United Kingdom, CB2 2QQ
Cardiff, United Kingdom, CF14 2TL
Chelsmford, United Kingdom, CM1 7ET
Colchester, United Kingdom, CO3 3NB
Dundee, United Kingdom, DD1 9SY
Edinburgh, United Kingdom, EH4 2XU
Epping, United Kingdom, CM16 6TN
Exeter, United Kingdom, EX2 5DW
Glasgow, United Kingdom, G12 0YN
Guildford, United Kingdom, GU2 5XX
Huddersfield, United Kingdom, HD3 3EA
Ipswich, United Kingdom, IP4 5PD
Leeds, United Kingdom, LS9 7TF
London, United Kingdom, EC1 A7BE
London, United Kingdom, SE1 9RT
London, United Kingdom, W2 1NY
London, United Kingdom, NW3 2QG
Manchester, United Kingdom, M20 4BX
Merseyside, United Kingdom, CH63 45Y
Newcastle Upon Tyne, United Kingdom, NE4 6BE
Northwood, United Kingdom, HA6 2RN
Peterborough, United Kingdom, PE 3 9GZ
Sheffield, United Kingdom, S1O 2SJ
Southampton, United Kingdom, SO16 6YD
Stoke-on-trent, United Kingdom, ST4 7LN
Truro, United Kingdom, TR1 3LJ
Wolverhampton, United Kingdom, WV10 0QP
Sponsors and Collaborators
Hoffmann-La Roche
Investigators
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

No publications provided

Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT00528567     History of Changes
Other Study ID Numbers: BO20289
Study First Received: September 11, 2007
Results First Received: February 28, 2013
Last Updated: September 17, 2013
Health Authority: France: AFSSAPS

Additional relevant MeSH terms:
Breast Neoplasms
Triple Negative Breast Neoplasms
Breast Diseases
Neoplasms
Neoplasms by Site
Skin Diseases
Bevacizumab
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Antineoplastic Agents
Growth Inhibitors
Growth Substances
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses

ClinicalTrials.gov processed this record on October 23, 2014